Day: Rnatics
7 Questions
Rnatics: Hope for pulmonary fibrosis
Rnatics is developing RCS-21, a novel inhalable drug for pneumonia and idiopathic pulmonary fibrosis. The startup was founded in 2021 as a spin-off of…
Deals
A milestone in the treatment of lung diseases? Rnatics receives 2.7 million euros.
Munich-based biotech startup Rnatics has secured €2.7 million in federal funding. The funds will be used for the clinical development of a…
Needs Review
Covid drug: Federal government supports Rnatics with 7 million euros
Rnatics, a startup at the Technical University of Munich, has developed an RNA-based drug to prevent inflammatory lung damage. This occurs particularly…
